TR200002400T2 - Merkezi sinir sisteminde östrejen noksanlığının hedefli olarak ikame edilmesine yarayan farmasötik terkipler - Google Patents

Merkezi sinir sisteminde östrejen noksanlığının hedefli olarak ikame edilmesine yarayan farmasötik terkipler

Info

Publication number
TR200002400T2
TR200002400T2 TR2000/02400T TR200002400T TR200002400T2 TR 200002400 T2 TR200002400 T2 TR 200002400T2 TR 2000/02400 T TR2000/02400 T TR 2000/02400T TR 200002400 T TR200002400 T TR 200002400T TR 200002400 T2 TR200002400 T2 TR 200002400T2
Authority
TR
Turkey
Prior art keywords
estrogen
effects
zns
central nervous
nervous system
Prior art date
Application number
TR2000/02400T
Other languages
English (en)
Inventor
Patchev Vladimir
Oettel Michael
Thieme Ina
Schwarz Sigfrid
R�mer Wolfgang
Original Assignee
Jenapharm Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998121831 external-priority patent/DE19821831A1/de
Application filed by Jenapharm Gmbh & Co.Kg filed Critical Jenapharm Gmbh & Co.Kg
Publication of TR200002400T2 publication Critical patent/TR200002400T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Abstract

Bulus steroyidlerinin baska organlari veya sistemleri etkilemeden merkezi sinir sisteminde (ZNS) östrejen noksanliginin hedefli olarak ikame edilmesine yarayan terkiplerin üretiminde kullanimiyla alakalidir. Bu steroyidlerin özelligi, 17a-estradiyol dahil olmak üzere sistemik etkili dogal ve sentetik östrojenlerin aksine selektif nörotrop östrojen benzeri transkrilipsiyon etkisi göstermeleridir. Seçilen steroyidlerin bulusa göre kullanimlarinda asagidaki etkilere sahip oldugu sasirtici bir biçimde tespit edilmistir: -merkezi sinir sisteminde östrejene bagimli jenlerin transkripsiyonu selektif biçimde etkilemek ve ilgili fizyolojik parametrelerin degisimini saglamak; -hücre yenileyici sistemin dokularinda biyolojik etkileri olmayan dozlarda ZNS-özel transkripsiyon tesirlerine sahip olmak; -ne 17b-estradiyolün etkili olmadigi dozlarda ZNS-özel transkripsiyon etkileri meydana getirmek; -ZNS'te östrejene bagimli jenlerin transkripsiyonunu ikincil olarak olusturulmus 17b DEVAMI VAR.
TR2000/02400T 1998-02-20 1999-02-10 Merkezi sinir sisteminde östrejen noksanlığının hedefli olarak ikame edilmesine yarayan farmasötik terkipler TR200002400T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19807264 1998-02-20
DE1998121831 DE19821831A1 (de) 1998-05-15 1998-05-15 Pharmazeutische Präparate zur gezielten Substitution des Estrogenmangels im Zentralnervensystem

Publications (1)

Publication Number Publication Date
TR200002400T2 true TR200002400T2 (tr) 2000-11-21

Family

ID=26044035

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02400T TR200002400T2 (tr) 1998-02-20 1999-02-10 Merkezi sinir sisteminde östrejen noksanlığının hedefli olarak ikame edilmesine yarayan farmasötik terkipler

Country Status (24)

Country Link
EP (1) EP1056460B1 (tr)
JP (1) JP2002503694A (tr)
KR (1) KR20010041107A (tr)
CN (1) CN1291102A (tr)
AT (1) ATE252388T1 (tr)
AU (1) AU739071C (tr)
BG (1) BG104689A (tr)
BR (1) BR9909205A (tr)
CA (1) CA2321498A1 (tr)
CZ (1) CZ291764B6 (tr)
DE (1) DE59907446D1 (tr)
EA (1) EA002707B1 (tr)
EE (1) EE03906B1 (tr)
HU (1) HUP0100742A3 (tr)
ID (1) ID27069A (tr)
IL (1) IL137727A0 (tr)
IS (1) IS5571A (tr)
NO (1) NO20004153L (tr)
NZ (1) NZ506049A (tr)
PL (1) PL342313A1 (tr)
SK (1) SK12152000A3 (tr)
TR (1) TR200002400T2 (tr)
UA (1) UA57830C2 (tr)
WO (1) WO1999042108A1 (tr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1310799B1 (en) 2001-11-07 2005-12-21 Schering AG In vitro screening for ligands of the estrogen receptor
CN112189624A (zh) * 2020-09-08 2021-01-08 山东第一医科大学(山东省医学科学院) 一种利用受体基因沉默技术构建和鉴定女性ad模型的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897389A (en) * 1984-10-29 1990-01-30 Chaovanee Aroonsakul Treating central nervous system diseases
US4791099A (en) * 1984-10-29 1988-12-13 Chaovanee Aroonsakul Method of treatment for central nervous system diseases such as Alzheimer's's disease
DE4239946C2 (de) * 1992-11-27 2001-09-13 Jenapharm Gmbh Estranderivate mit einer 14alpha,15alpha-Methylengruppe und Verfahren zu ihrer Herstellung
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
DE4338314C1 (de) * 1993-11-10 1995-03-30 Jenapharm Gmbh Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen
DE4429397C2 (de) * 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE19524937A1 (de) * 1995-07-08 1997-01-09 Jenapharm Gmbh Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen und zur medikamentösen Substitution beim Mann
AU6507996A (en) * 1995-07-24 1997-02-18 University Of Florida Research Foundation, Inc. Use of non-estrogen polycyclic phenol compounds for the manufacture of a medicament for conferring neuroprotection to cells

Also Published As

Publication number Publication date
CA2321498A1 (en) 1999-08-26
DE59907446D1 (de) 2003-11-27
KR20010041107A (ko) 2001-05-15
NZ506049A (en) 2002-09-27
EA200000858A1 (ru) 2001-04-23
EP1056460B1 (de) 2003-10-22
NO20004153D0 (no) 2000-08-18
ATE252388T1 (de) 2003-11-15
EE03906B1 (et) 2002-12-16
EP1056460A1 (de) 2000-12-06
AU739071B2 (en) 2001-10-04
IL137727A0 (en) 2001-10-31
HUP0100742A3 (en) 2002-07-29
BG104689A (en) 2001-04-30
WO1999042108A1 (de) 1999-08-26
HUP0100742A2 (hu) 2001-09-28
SK12152000A3 (sk) 2001-02-12
AU739071C (en) 2002-04-11
CZ20002938A3 (cs) 2001-01-17
JP2002503694A (ja) 2002-02-05
ID27069A (id) 2001-02-22
PL342313A1 (en) 2001-06-04
EE200000477A (et) 2001-12-17
AU2920999A (en) 1999-09-06
UA57830C2 (uk) 2003-07-15
BR9909205A (pt) 2000-11-14
CN1291102A (zh) 2001-04-11
EA002707B1 (ru) 2002-08-29
NO20004153L (no) 2000-10-09
IS5571A (is) 2000-07-24
CZ291764B6 (cs) 2003-05-14

Similar Documents

Publication Publication Date Title
FI963103A0 (fi) Ei-virusvektori
ATE311184T1 (de) 1-benzyl-3-(substituiertes-hetaryl)-kondensiert n pyrazol-derivaten zur behandlung von erkrankungen des herz-kreislaufsystems und des zentralnervensystems
DE69534669D1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
TR199800028T1 (tr) Hücre yapismasini önleyen ajanlar.
TR200000289T2 (tr) Kimyasal bileşimler
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
PT912185E (pt) Novas formulacoes farmaceuticas contendo derivados de ester nitrato de esteroides proveitosos como farmacos anti-inflamatorios
ZA967759B (en) Selectively functionalizable desdendrimers.
TR200002400T2 (tr) Merkezi sinir sisteminde östrejen noksanlığının hedefli olarak ikame edilmesine yarayan farmasötik terkipler
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
MY120219A (en) Composition for the treatment of rice seeds
DE59710660D1 (de) Kombination von dehydroepiandrosteron und aromatasehemmern und verwendung dieser kombination zur herstellung eines arzneimittels zur behandlung eines relativen und absoluten androgenmangels beim mann
HK1041884A1 (zh) Tan-1057衍生物
ATE211482T1 (de) Selektive inhibitoren des faktors x, eine azepinonstruktur enthaltend
DE69407057D1 (de) 1,3.5 (10) - estratriene derivate mit oraler wirkung
ES2133918T3 (es) Nuevos esteroides seco-d activos en el sistema cardiovascular y composiciones farmaceuticas que los contienen.
DE59811153D1 (de) Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe
ES2150996T3 (es) Corticoides y composiciones farmaceuticas y cosmeticas.
ES2155911T3 (es) Derivados de alcanfor como nuevos odorantes.
ATE42201T1 (de) Verwendung von phytosterolglycosiden zur herstellung von arzneimitteln zur behandlung von erhoehtem 5(6)alpha-epoxycholesterolgehalt.
CA2421302A1 (en) 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds